榮昌生物(09995.HK)與參天中國達成RC28-E注射液獨家許可協議 首付款2.5億元
格隆匯8月19日丨榮昌生物(09995.HK)發佈公告,2025年8月18日,公司及參天製藥(中國)有限公司(“參天中國”)訂立許可協議,據此,公司將具有自主知識產權的RC28-E注射液(“許可產品”)有償許可給參天中國,參天中國將獲得在大中華區(即中國、中國香港、中國澳門及中國臺灣)及韓國、泰國、越南、新加坡、菲律賓、印度尼西亞及馬來西亞(“許可範圍”)的獨家開發、生產和商業化權利,而本公司將保留RC28-E在上述許可範圍以外的全球獨家權益。
根據許可協議及在其條款及條件的規限下,公司將從參天中國取得(i)2.5億元人民幣的不可退還且不可抵扣的首付款;(ii)最高可達5.2億元人民幣的開發及監管里程碑付款;以及(ii)最高可達5.25億元人民幣的銷售里程碑付款。此外,公司還將根據在許可範圍內的產品銷售額收取高個位數至雙位數百分比的梯度銷售分成。許可協議自2025年8月18日起開始生效,除非依據許可協議提前終止,否則將持續有效。
許可協議的簽訂將快速推動RC28-E的市場準入與患者覆蓋,顯著縮短商業化週期,爲眼底疾病的治療提供創新且高效的解決方案。參天中國是日本參天製藥株式會社(“參天製藥”)的全資子公司,負責參天製藥在中國市場的業務拓展。參天製藥是一家擁有130餘年歷史的日本眼科領域專業企業,總部位於日本大阪,於1964年6月在東京證券交易所上市(股票代碼:4536.T),專注於眼科藥品的研發、生產和銷售,是全球眼科市場的領導者之一,主營領域包括眼科處方藥、非處方產品、醫療器械及創新服務模式,產品覆蓋青光眼、乾眼症、近視防控、視網膜病變等多個治療領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.